HPLC purity
Reverse-phase HPLC with UV detection; purity target reported per lot with related-substance reporting on request.
ARA-290HPLC ≥ 99%MS confirmed10mg
Vial illustrations reflect supplied lyophilized format. Distribution scope and destination market confirmed before invoicing.
| Compound | ARA-290 (Cibinetide) |
|---|---|
| CAS number | 1208243-50-8 |
| Molecular formula | C51H84N16O21 |
| Molecular weight | 1257.3 g/mol |
| Sequence | pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (11-mer, pyroglutamate N-terminus; one-letter Q*EQLERALNSS) |
| Form | Lyophilized powder, glass vial |
| Purity target | ≥ 99% by HPLC |
| Vial formats | 10mg / 16mg |
| Documentation | Batch-document availability confirmed by product, specification and applicable lot |
| Distribution scope | Research use, worldwide |
| Storage | Store lyophilized powder at -20°C, protected from light and moisture; stable at short-term ambient for shipping. After reconstitution, keep refrigerated at 2-8°C and use within the validated window. Consult the batch COA for lot-specific handling. |
MOQ & lead time
| Tier | Quantity | Lead time |
|---|---|---|
| OEM lot | 50 kits (500 vials) | 3–7 days |
| Production lot | 500–1,000 vials | 10–14 days |
| OEM repeat | 1,000+ vials | 14–18 days, scheduled |
Supplied as a research-use peptide. Every quote confirms current-batch COA, purity, destination market and buyer track before invoicing.
Overview
About ARA-290 (Cibinetide).
ARA-290 is an EPO-derived tissue-protective peptide (INN: cibinetide) that in published research selectively engages the innate repair receptor (IRR), a heterodimer of the EPO receptor and the beta-common receptor CD131, rather than the classical erythropoietic EPO receptor. This signaling has been studied for anti-inflammatory and tissue-repair effects, notably in small-fiber and diabetic neuropathy models, without stimulating red-cell production.
Documentation
Batch documentation support for ARA-290 (Cibinetide) lots.
batch-document availability confirmed by product, specification and applicable lot. Distribution scope confirmed before invoicing.
MS identity
Mass spectrometry identity confirmation against the ARA-290 (Cibinetide) reference profile.
Lot traceability
Compound prefix and lot serial printed on the vial label and repeated in the document pack and carton.
FAQ
ARA-290 (Cibinetide) — frequently asked by B2B buyers.
What documentation ships with each ARA-290 (Cibinetide) batch?
For the applicable lot, Pepti confirms whether available documentation includes a Certificate of Analysis reporting HPLC purity, mass-spec (MS) identity confirmation, appearance, and net peptide content. Third-party or additional analytical documentation can be arranged on request for qualified B2B accounts.
What vial sizes and minimum order quantity does Pepti offer?
ARA-290 is stocked as lyophilized powder in 10mg and 16mg vials, with a standard MOQ of 50 kits (500 vials). Larger bulk quantities and custom fill weights are quoted per RFQ.
What purity can we expect?
A ≥99% HPLC purity target may be quoted; the acceptance criterion and actual result must be confirmed for the applicable product and lot. Tighter or custom specifications can be quoted for volume orders.
Do you support private-label and custom OEM packaging?
Yes. As an OEM/private-label supplier we can provide custom vial labeling, box/kit configurations, and documentation formatting. Share your artwork and specification and we will confirm feasibility during quoting.
Is ARA-290 sold for therapeutic or consumer use?
No. All material is supplied strictly for laboratory research and manufacturing input use only, not for consumer or veterinary consumption, and is not a drug or medical product. Buyers are responsible for compliance with import and end-use regulations in their jurisdiction.
Related compounds
Related research peptides.
COA library search
Search public COAs for this product.
The public COA library is being expanded by product and specification. Use the search link below to check current public records for this item.